法国多中心随机试验:肥胖危重患者拔管后无创通气的效果
在法国39个ICU进行的多中心、非盲、实用性随机对照试验,纳入981例肥胖危重拔管患者,比较无创通气(NIV)与氧疗(HFNO或标准氧)对拔管后3天内治疗失败的影响。
要点
- 肥胖危重患者拔管后使用NIV可显著降低3天内治疗失败风险。
- 治疗失败差异主要源于氧疗组患者转换为NIV,再插管率未显著降低。
- NIV策略对医疗或外科患者的效果无显著差异。
核心结论
- 肥胖危重成人拔管后使用NIV可有效减少3天内治疗失败。
- 但主要结局差异多因氧疗组患者转换为NIV,需更多证据证明NIV改善患者中心结局。
研究设计与样本
- 多中心、平行组、实用性随机对照试验,在法国39个ICU进行。
- 纳入981例肥胖危重拔管患者,随机1:1分为NIV组或氧疗组,氧疗组内再随机1:1分为HFNO或标准氧。
- 主要结局为拔管后3天内治疗失败(再插管、转换治疗或提前终止研究治疗的复合终点),按意向性分析。
主要发现
- 医疗或外科状态未改变NIV对治疗失败率的影响。
- 未报告严重不良事件。
临床怎么用
- 对于肥胖危重患者,拔管后可采用NIV以降低治疗失败风险。
- 需注意治疗失败差异主要来自氧疗组转换为NIV,再插管获益尚不明确。
局限性
- 研究为非盲设计,但统计学家设盲。
- 主要结局差异多因氧疗组患者转换为NIV,需更多证据确认对患者中心结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-invasive ventilation (NIV) and oxygen therapy (high-flow nasal oxygen [HFNO] or standard oxygen) following extubation have never been compared in critically ill patients with obesity. We aimed to compare NIV (alternating with HFNO or standard oxygen) and oxygen therapy (HFNO or standard oxygen) following extubation of critically ill patients with obesity. METHODS: In this multicentre, parallel group, pragmatic randomised controlled trial, conducted in 39 intensive care units in France, critically ill patients with obesity undergoing extubation were randomly assigned (1:1) to either the NIV group or the oxygen therapy group. Two randomisations were performed: first, randomisation to either NIV or oxygen therapy, and second, randomisation to either HFNO or standard oxygen (also 1:1), which was nested within the first randomisation. Blinding of the randomisation was not possible, but the statistician was masked to group assignment. The primary outcome was treatment failure within 3 days after extubation, a composite of reintubation for mechanical ventilation, switch to the other study treatment, or premature discontinuation of study treatment. The primary outcome was analysed by intention to treat. Effect of medical and surgical status was assessed. The reintubation within 3 days was analysed by intention to treat and after a post-hoc crossover analysis. This study is registered with ClinicalTrials.gov, number NCT04014920. FINDINGS: From Oct 2, 2019, to July 17, 2021, of the 1650 screened patients, 981 were enrolled. Treatment failure occurred in 66 (13·5%) of 490 patients in the NIV group and in 130 (26·5%) of 491 patients in the oxygen-therapy group (relative risk 0·43; 95% CI 0·31-0·60, p<0·0001). Medical or surgical status did not modify the effect of NIV group on the treatment-failure rate. Reintubation within 3 days after extubation was similar in the non-invasive ventilation group and in the oxygen therapy group in the intention-to-treat analysis (48 (10%) of 490 patients and 59 (12%) of 491 patients, p=0·26) and lower in the NIV group than in the oxygen-therapy group in the post-hoc cross-over (51 (9%) of 560 patients and 56 (13%) of 421 patients, p=0·037) analysis. No severe adverse events were reported. INTERPRETATION: Among critically ill adults with obesity undergoing extubation, the use of NIV was effective to reduce treatment-failure within 3 days. Our results are relevant to clinical practice, supporting the use of NIV after extubation of critically ill patients with obesity. However, most of the difference in the primary outcome was due to patients in the oxygen therapy group switching to NIV, and more evidence is needed to conclude that an NIV strategy leads to improved patient-centred outcomes. FUNDING: French Ministry of Health.
引用
- De Jong A, Bignon A, Stephan F, et al. Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial. Lancet Respir Med. 2023. PMID: 36693403. doi:10.1016/S2213-2600(22)00529-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。